FDA Investigator Anthony R Bucks

Anthony R Bucks has conducted inspections on 37 sites in 1 countries as of 10 Jun 2013. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
37
Last Inspection Date:
10 Jun 2013
Investigator Role:
FDA Investigation Participant
Redica ID:
100008525
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Anthony R Bucks:
Adree N Anderson, Alan L Brend, Alan L Truong, Alex M Viehmann, Amir A Abdalla, Amy E Devine, Ana Paulap Sandee, Andrew A Hoopes, April K Hill, Aref Mel Demerdash, Ashley A Mutawakkil, Audrey N Vigil, Barbara I Rogolsky, Beatrix D Arevalo, Beatrix D Hippe, Blondell W Johnson, Brenda C Hamilton, Brent T Hall, Brett R Havranek, Brittany D Terhar, Bryan S Roddy, Candace S Tucker, Carl A Huffman, III, Ceisha C Ukatu, Chih Jung Hsu, PhD, Chilton L Ng, Christine A Harman, PhD, Cody D Rickman, Cody J Alley, Cynthia L Evitt, Cynthia M Goudeau, Damaris Y Hernandez, Danial S Hutchison, Daniel R Hurt, Darrah, David J Eide, David L Miser, Dawn C Olenjack, Dewayne E Whitlock, Dina K West, Donald L Myers, Edward E Lockwood (EEL), Elmina E Mboh, Emilio O Escobar, Eric C Nielsen, Eric M Mueller, PharmD, Eric M Padgett, Erika V Butler, Farhana Khan, Frank Wackes, Georgia A Layloff, Gloria J Champagne, Gretchen Lf Trendel, Gwyn G Dickinson, Hector A Carrero, Helen Y Saccone, Hongjian Ding, Jacob G Lutz, Jacqueline Mdiaz Albertini, James D Planchon, James I Giefer, Janet B Abt, Janna C Hutchinson, Jason H Wieners, Jazmine N Still, Jeannie M Vonderbrink, Jeffery A Hangartner, Jeffery L Sumter, Jennifer Cahill, Jill J Tillman, John C Mcmichael, Johnson, Jonathan G Gayechuway, Jonathan R Campos, Joohi Castelvetere, Joseph A Piechocki, Joseph R Lambert, Joseph R Strelnik, Juandria V Williams, Justin A Boyd, Kara L Roden, Karen C Daugherty, Karen M Cruz Arenas, Karen M Montgomery (KMM), Karthik B Iyer, Kathleen B Swat, Kathleen M Bradley, Kellia N Hicks, Kelly D Sheppard, Kelly K Nachtigal, Ken L Bowers, Kendra A Biddick, Kevin D Kallander, Kshitij A Patkar, LCDR Matthew J Morrison, Lewis K Antwi, Linda K Cline, Lisa L Flores, Lisa L Gilliam, Margaret A Smithers, Mark S Ross, Mary K Concannon, Mary L Schuckmann, Matthew H Hunt, Matthew M Schuckmann, Matthew Ondeck, Matthew R Sleeter, Megan M Kirk, Meisha Waters, Michael D Porter, Michele L Obert, Michele Perry Williams, Minerva Rogers, Monica Cburgos Garcia, Monica E Murie, Monica M Mcclure, Nancy G Schmidt, Neal L Adams, Omotunde O Osunsanmi, Pamela L Velez Vega, Patrick L Wisor, Paula A Trost, Peng Zhou, Philip J Boston, Phillip M Pontikos, Rachel Collen, Ralph H Vocque, Raymond Valdivia, Rebecca Rodriguez, Richard L Rutherford, Rick L Friedman, Rita K Kabaso, Robert J Ham, Robin K Hatfield, Robin K Reel, Rohit B Kolhatkar, Samuel K Gibbons, Jr, Sandra A Boyd, Sandra A Hughes, Sarah E Rhoades, Scott A Golladay, Scott A Jepson, Shafiq S Ahadi, Shanna R Haden, Sharon K Thoma, PharmD, Sherry G Bous, Shirley J Berryman, Sidney B Priesmeyer, Simone E Pitts, Sina Shojaee, Steven D Kehoe, Steven P Donald, Susan M Jackson, Susanna E Ford, Tamara J Umscheid, Tara L Breckenridge, Tara L Greene, Tara L King, Thomas J Arista, Thuy T Nguyen, LCDR, Tiara Nbrown Crosen, Tonya R Johnson, Torrey M Ward, Trevor A Parker, Verlinda A Narcisse, Veronica L Call, Victoria A Wagoner, Walsworth, Warren J Lopicka, Wayne D Mcgrath, William C Corley, William Hallett, PhD, Zachary A Bogorad, Zedong Dong, Zhong Li, PhD, Zi Qiang Gu

Anthony R Bucks's Documents

Publish Date Document Type Title
December, 2011 FDA 483 Legacy Pharmaceutical Packaging, LLC - Form 483, 2011-12-20
January, 2013 FDA 483 Nostrum Laboratories, Inc. - Form 483, 2013-01-30
February, 2013 FDA 483 Huvepharma, Inc. - Form 483, 2013-02-28
October, 2012 FDA 483 Hospira, Inc. - Form 483, 2012-10-24
April, 2013 FDA 483 Meridian Medical Technologies Inc., A Pfizer Company - Form 483, 2013-04-29
March, 2013 FDA 483 Foundation Care LLC - Form 483, 2013-03-19
July, 2012 FDA 483 Marcus Research Laboratory, Inc. - Form 483, 2012-07-06
January, 2013 EIR Nostrum Laboratories, Inc. - EIR, 2013-01-30
April, 2011 FDA 483 Sigma-Aldrich Mfg LLC - Form 483, 2011-04-25
April, 2011 FDA 483 Sigma-Aldrich Mfg LLC - Form 483, 2011-04-25
February, 2012 FDA 483 Alcami Carolinas Corporation - Form 483, 2012-02-03
December, 2011 FDA 483 Forest Pharmaceuticals Inc - Form 483, 2011-12-02
July, 2012 EIR Marcus Research Laboratory, Inc. - EIR, 2012-07-06
January, 2013 FDA 483 Mobius Therapeutics LLC - Form 483, 2013-01-17
November, 2011 FDA 483 GlaxoSmithKline Consumer Healthcare Holdings (US) LLC - Form 483, 2011-11-02
May, 2011 EIR PD International, LLC. - EIR, 2011-05-27
February, 2011 FDA 483 PETNET Solutions, Inc.,ST. LOUIS, MO - Form 483, 2011-02-09
February, 2012 FDA 483 Response Alcami Carolinas Corporation - Form 483R, 2012-02-21
October, 2012 FDA 483 Response Hospira, Inc. - Form 483R, 2012-11-14
February, 2012 EIR Alcami Carolinas Corporation - EIR, 2012-02-03
April, 2012 FDA 483 Reliable Biopharmaceutical LLC - Form 483, 2012-04-27
January, 2013 EIR Mobius Therapeutics LLC - EIR, 2013-01-17
February, 2011 EIR PETNET Solutions, Inc.,ST. LOUIS, MO - EIR, 2011-02-09
October, 2012 EIR Hospira, Inc. - EIR, 2012-10-24
June, 2013 FDA 483 Legacy Pharmaceutical Packaging, LLC - Form 483, 2013-06-18
March, 2013 FDA 483 Response Foundation Care LLC - Form 483R, 2013-04-09

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more